A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs
Article first published online: 26 NOV 2013
© 2013 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Diabetes, Obesity and Metabolism
Volume 16, Issue 3, pages 273–275, March 2014
How to Cite
Funch, D., Gydesen, H., Tornøe, K., Major-Pedersen, A. and Chan, K. A. (2014), A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes, Obesity and Metabolism, 16: 273–275. doi: 10.1111/dom.12230
- Issue published online: 4 FEB 2014
- Article first published online: 26 NOV 2013
- Accepted manuscript online: 6 NOV 2013 09:55PM EST
- Manuscript Accepted: 29 OCT 2013
- Manuscript Revised: 13 AUG 2013
- Manuscript Received: 24 JUL 2013
- observational study
We evaluated the relationship between liraglutide and acute pancreatitis or pancreatic cancer in an ongoing post-marketing safety assessment programme.
Initiators of liraglutide, exenatide, metformin, pioglitazone or groups containing initiators of dipeptidyl peptidase-4 inhibitors or sulfonylureas were identified in a US commercial health insurance claims database (1 February 2010 to 31 March 2013) and followed for a median of 15 months. We estimated incidence rates (IR/100 000 person-years), rate ratio (RR) and 95% confidence intervals (CI) of new insurance claims with diagnoses of primary inpatient acute pancreatitis or pancreatic cancer from Poisson regression models.
The IR for acute pancreatitis for liraglutide was 187.5 compared with 154.4 for all non-glucagon-like peptide-1 (GLP-1)-based therapies (adjusted RR 1.10; CI 0.81–1.49). The IR for pancreatic cancer was 19.9 for liraglutide compared with 33.0 for all non-GLP-1-based therapies (adjusted RR 0.65; 95% CI 0.26–1.60).
We did not observe excess risk of either outcome associated with liraglutide relative to individual or pooled comparator drugs.